ID   ZAP70_HUMAN             Reviewed;         619 AA.
AC   P43403; A6NFP4; Q6PIA4; Q8IXD6; Q9UBS6;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   10-MAY-2017, entry version 202.
DE   RecName: Full=Tyrosine-protein kinase ZAP-70;
DE            EC=2.7.10.2;
DE   AltName: Full=70 kDa zeta-chain associated protein;
DE   AltName: Full=Syk-related tyrosine kinase;
GN   Name=ZAP70; Synonyms=SRK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH
RP   CD247, TISSUE SPECIFICITY, AND PHOSPHORYLATION.
RX   PubMed=1423621; DOI=10.1016/0092-8674(92)90598-7;
RA   Chan A.C., Iwashima M., Turck C.W., Weiss A.;
RT   "ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR
RT   zeta chain.";
RL   Cell 71:649-662(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Leukocyte;
RX   PubMed=14985102; DOI=10.1016/j.bbrc.2004.01.127;
RA   Kuroyama H., Ikeda T., Kasai M., Yamasaki S., Tatsumi M., Utsuyama M.,
RA   Saito T., Hirokawa K.;
RT   "Identification of a novel isoform of ZAP-70, truncated ZAP kinase.";
RL   Biochem. Biophys. Res. Commun. 315:935-941(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Blood, and Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 521-547, VARIANT IMD48 LEU-GLU-GLN-541
RP   INS, FUNCTION, AND INVOLVEMENT IN IMD48.
RC   TISSUE=Lymphoid tissue;
RX   PubMed=8124727; DOI=10.1016/0092-8674(94)90368-9;
RA   Arpaia E., Shahar M., Dadi H., Cohen A., Roifman C.M.;
RT   "Defective T cell receptor signaling and CD8+ thymic selection in
RT   humans lacking zap-70 kinase.";
RL   Cell 76:947-958(1994).
RN   [6]
RP   CHARACTERIZATION OF TAM-BINDING.
RX   PubMed=7528772; DOI=10.1084/jem.181.1.375;
RA   Isakov N., Wange R.L., Burgess W.H., Watts J.D., Aebersold R.,
RA   Samelson L.E.;
RT   "ZAP-70 binding specificity to T cell receptor tyrosine-based
RT   activation motifs: the tandem SH2 domains of ZAP-70 bind distinct
RT   tyrosine-based activation motifs with varying affinity.";
RL   J. Exp. Med. 181:375-380(1995).
RN   [7]
RP   PHOSPHORYLATION AT TYR-492 AND TYR-493, AND MUTAGENESIS OF TYR-492 AND
RP   TYR-493.
RX   PubMed=7781602;
RA   Chan A.C., Dalton M., Johnson R., Kong G.H., Wang T., Thoma R.,
RA   Kurosaki T.;
RT   "Activation of ZAP-70 kinase activity by phosphorylation of tyrosine
RT   493 is required for lymphocyte antigen receptor function.";
RL   EMBO J. 14:2499-2508(1995).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF LCP2.
RX   PubMed=8702662; DOI=10.1074/jbc.271.33.19641;
RA   Bubeck Wardenburg J., Fu C., Jackman J.K., Flotow H., Wilkinson S.E.,
RA   Williams D.H., Johnson R., Kong G., Chan A.C., Findell P.R.;
RT   "Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is
RT   required for T-cell receptor function.";
RL   J. Biol. Chem. 271:19641-19644(1996).
RN   [9]
RP   PHOSPHORYLATION AT TYR-292, AND MUTAGENESIS OF TYR-292.
RX   PubMed=8943331; DOI=10.1128/MCB.16.12.6765;
RA   Zhao Q., Weiss A.;
RT   "Enhancement of lymphocyte responsiveness by a gain-of-function
RT   mutation of ZAP-70.";
RL   Mol. Cell. Biol. 16:6765-6774(1996).
RN   [10]
RP   INTERACTION WITH VAV1, AND MUTAGENESIS OF TYR-315.
RX   PubMed=9151714; DOI=10.1084/jem.185.10.1877;
RA   Wu J., Zhao Q., Kurosaki T., Weiss A.;
RT   "The Vav binding site (Y315) in ZAP-70 is critical for antigen
RT   receptor-mediated signal transduction.";
RL   J. Exp. Med. 185:1877-1882(1997).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=9378960;
RA   Gary-Gouy H., Lang V., Sarun S., Boumsell L., Bismuth G.;
RT   "In vivo association of CD5 with tyrosine-phosphorylated ZAP-70 and
RT   p21 phospho-zeta molecules in human CD3+ thymocytes.";
RL   J. Immunol. 159:3739-3747(1997).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF LAT.
RX   PubMed=9489702; DOI=10.1016/S0092-8674(00)80901-0;
RA   Zhang W., Sloan-Lancaster J., Kitchen J., Trible R.P., Samelson L.E.;
RT   "LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor
RT   to cellular activation.";
RL   Cell 92:83-92(1998).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9813084; DOI=10.1083/jcb.143.3.613;
RA   Sloan-Lancaster J., Presley J., Ellenberg J., Yamazaki T.,
RA   Lippincott-Schwartz J., Samelson L.E.;
RT   "ZAP-70 association with T cell receptor zeta (TCRzeta): fluorescence
RT   imaging of dynamic changes upon cellular stimulation.";
RL   J. Cell Biol. 143:613-624(1998).
RN   [14]
RP   PHOSPHORYLATION AT TYR-315 AND TYR-319, AND MUTAGENESIS OF TYR-315 AND
RP   TYR-319.
RX   PubMed=10037717; DOI=10.1074/jbc.274.10.6285;
RA   Di Bartolo V., Mege D., Germain V., Pelosi M., Dufour E., Michel F.,
RA   Magistrelli G., Isacchi A., Acuto O.;
RT   "Tyrosine 319, a newly identified phosphorylation site of ZAP-70,
RT   plays a critical role in T cell antigen receptor signaling.";
RL   J. Biol. Chem. 274:6285-6294(1999).
RN   [15]
RP   INTERACTION WITH CBL AND SLA.
RX   PubMed=10449770; DOI=10.1073/pnas.96.17.9775;
RA   Tang J., Sawasdikosol S., Chang J.-H., Burakoff S.J.;
RT   "SLAP, a dimeric adapter protein, plays a functional role in T cell
RT   receptor signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:9775-9780(1999).
RN   [16]
RP   FUNCTION IN CD3Z UBIQUITINATION.
RX   PubMed=11353765; DOI=10.1074/jbc.M010738200;
RA   Wang H.Y., Altman Y., Fang D., Elly C., Dai Y., Shao Y., Liu Y.C.;
RT   "Cbl promotes ubiquitination of the T cell receptor zeta through an
RT   adaptor function of Zap-70.";
RL   J. Biol. Chem. 276:26004-26011(2001).
RN   [17]
RP   INTERACTION WITH FCRL3.
RX   PubMed=12051764; DOI=10.1016/S0006-291X(02)00332-7;
RA   Xu M.-J., Zhao R., Cao H., Zhao Z.J.;
RT   "SPAP2, an Ig family receptor containing both ITIMs and ITAMs.";
RL   Biochem. Biophys. Res. Commun. 293:1037-1046(2002).
RN   [18]
RP   MUTAGENESIS OF TYR-315.
RX   PubMed=11828374;
RX   DOI=10.1002/1521-4141(200202)32:2<568::AID-IMMU568>3.0.CO;2-Q;
RA   Di Bartolo V., Malissen M., Dufour E., Sechet E., Malissen B.,
RA   Acuto O.;
RT   "Tyrosine 315 determines optimal recruitment of ZAP-70 to the T cell
RT   antigen receptor.";
RL   Eur. J. Immunol. 32:568-575(2002).
RN   [19]
RP   INTERACTION WITH SHB.
RX   PubMed=12084069; DOI=10.1046/j.1432-1033.2002.03008.x;
RA   Lindholm C.K., Henriksson M.L., Hallberg B., Welsh M.;
RT   "Shb links SLP-76 and Vav with the CD3 complex in Jurkat T cells.";
RL   Eur. J. Biochem. 269:3279-3288(2002).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=12522270; DOI=10.1073/pnas.2436191100;
RA   Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T.,
RA   Ericson C., Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.;
RT   "Profiling of tyrosine phosphorylation pathways in human cells using
RT   mass spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-289, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [22]
RP   INTERACTION WITH NFAM1.
RX   PubMed=15143214; DOI=10.1073/pnas.0401119101;
RA   Ohtsuka M., Arase H., Takeuchi A., Yamasaki S., Shiina R., Suenaga T.,
RA   Sakurai D., Yokosuka T., Arase N., Iwashima M., Kitamura T.,
RA   Moriya H., Saito T.;
RT   "NFAM1, an immunoreceptor tyrosine-based activation motif-bearing
RT   molecule that regulates B cell development and signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:8126-8131(2004).
RN   [23]
RP   PHOSPHORYLATION BY LCK.
RX   PubMed=16339550; DOI=10.4049/jimmunol.175.12.8123;
RA   Gelkop S., Gish G.D., Babichev Y., Pawson T., Isakov N.;
RT   "T cell activation-induced CrkII binding to the Zap70 protein tyrosine
RT   kinase is mediated by Lck-dependent phosphorylation of Zap70 tyrosine
RT   315.";
RL   J. Immunol. 175:8123-8132(2005).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-248, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [25]
RP   TISSUE SPECIFICITY.
RX   PubMed=16467082; DOI=10.1158/1078-0432.CCR-05-1531;
RA   Crespo M., Villamor N., Gine E., Muntanola A., Colomer D.,
RA   Marafioti T., Jones M., Camos M., Campo E., Montserrat E., Bosch F.;
RT   "ZAP-70 expression in normal pro/pre B cells, mature B cells, and in
RT   B-cell acute lymphoblastic leukemia.";
RL   Clin. Cancer Res. 12:726-734(2006).
RN   [26]
RP   DEPHOSPHORYLATION BY PTN22.
RX   PubMed=16461343; DOI=10.1074/jbc.M600498200;
RA   Wu J., Katrekar A., Honigberg L.A., Smith A.M., Conn M.T., Tang J.,
RA   Jeffery D., Mortara K., Sampang J., Williams S.R., Buggy J.,
RA   Clark J.M.;
RT   "Identification of substrates of human protein-tyrosine phosphatase
RT   PTPN22.";
RL   J. Biol. Chem. 281:11002-11010(2006).
RN   [27]
RP   REVIEW ON FUNCTION.
RX   PubMed=19290920; DOI=10.1111/j.1600-065X.2008.00753.x;
RA   Au-Yeung B.B., Deindl S., Hsu L.Y., Palacios E.H., Levin S.E.,
RA   Kuriyan J., Weiss A.;
RT   "The structure, regulation, and function of ZAP-70.";
RL   Immunol. Rev. 228:41-57(2009).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-292, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [29]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-603, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [30]
RP   FUNCTION, AND DOMAIN.
RX   PubMed=20135127; DOI=10.1007/s00281-010-0196-x;
RA   Fischer A., Picard C., Chemin K., Dogniaux S., le Deist F., Hivroz C.;
RT   "ZAP70: a master regulator of adaptive immunity.";
RL   Semin. Immunopathol. 32:107-116(2010).
RN   [31]
RP   FUNCTION, INTERACTION WITH OTUD7B AND UBASH3B, UBIQUITINATION AT
RP   LYS-544, IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF
RP   LYS-304; LYS-538 AND LYS-544.
RX   PubMed=26903241; DOI=10.1084/jem.20151426;
RA   Hu H., Wang H., Xiao Y., Jin J., Chang J.H., Zou Q., Xie X., Cheng X.,
RA   Sun S.C.;
RT   "Otud7b facilitates T cell activation and inflammatory responses by
RT   regulating Zap70 ubiquitination.";
RL   J. Exp. Med. 213:399-414(2016).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 3-256 IN COMPLEX WITH CD247,
RP   AND INTERACTION WITH CD247.
RX   PubMed=7659156; DOI=10.1038/377032a0;
RA   Hatada M.H., Lu X., Laird E.R., Green J., Morgenstern J.P., Lou M.,
RA   Marr C.S., Phillips T.B., Ram M.K., Theriault K., Zoller M.J.,
RA   Karas L.K.;
RT   "Molecular basis for interaction of the protein tyrosine kinase ZAP-70
RT   with the T-cell receptor.";
RL   Nature 377:32-38(1995).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 286-297 IN COMPLEX WITH CBL,
RP   AND INTERACTION WITH CBL.
RX   PubMed=10078535; DOI=10.1038/18050;
RA   Meng W., Sawasdikosol S., Burakoff S.J., Eck M.J.;
RT   "Structure of the amino-terminal domain of Cbl complexed to its
RT   binding site on ZAP-70 kinase.";
RL   Nature 398:84-90(1999).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 289-297 IN COMPLEX WITH CBL
RP   AND UBE2L3.
RX   PubMed=10966114; DOI=10.1016/S0092-8674(00)00057-X;
RA   Zheng N., Wang P., Jeffrey P.D., Pavletich N.P.;
RT   "Structure of a c-Cbl-UbcH7 complex: RING domain function in
RT   ubiquitin-protein ligases.";
RL   Cell 102:533-539(2000).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-256.
RX   PubMed=12450381; DOI=10.1021/bi026465e;
RA   Folmer R.H., Geschwindner S., Xue Y.;
RT   "Crystal structure and NMR studies of the apo SH2 domains of ZAP-70:
RT   two bikes rather than a tandem.";
RL   Biochemistry 41:14176-14184(2002).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 327-606 IN COMPLEX WITH
RP   STAUROSPORINE, CATALYTIC ACTIVITY, ACTIVE SITE, MUTAGENESIS OF
RP   ASP-479, AND ENZYME REGULATION.
RX   PubMed=15292186; DOI=10.1074/jbc.M407096200;
RA   Jin L., Pluskey S., Petrella E.C., Cantin S.M., Gorga J.C.,
RA   Rynkiewicz M.J., Pandey P., Strickler J.E., Babine R.E., Weaver D.T.,
RA   Seidl K.J.;
RT   "The three-dimensional structure of the ZAP-70 kinase domain in
RT   complex with staurosporine: implications for the design of selective
RT   inhibitors.";
RL   J. Biol. Chem. 279:42818-42825(2004).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1-606 OF MUTANT ASN-461 IN
RP   COMPLEX WITH MAGNESIUM AND ATP ANALOG, ACTIVE SITE, AND MUTAGENESIS OF
RP   TRP-131; LEU-133; ALA-141; SER-144; GLN-145; PRO-147; TYR-315;
RP   TYR-319; ASP-461; TYR-597 AND TYR-598.
RX   PubMed=17512407; DOI=10.1016/j.cell.2007.03.039;
RA   Deindl S., Kadlecek T.A., Brdicka T., Cao X., Weiss A., Kuriyan J.;
RT   "Structural basis for the inhibition of tyrosine kinase activity of
RT   ZAP-70.";
RL   Cell 129:735-746(2007).
RN   [38]
RP   VARIANT IMD48 ARG-518.
RX   PubMed=8202713; DOI=10.1126/science.8202713;
RA   Chan A.C., Kadlecek T.A., Elder M.E., Filipovich A.H., Kuo W.-L.,
RA   Iwashima M., Parslow T.G., Weiss A.;
RT   "ZAP-70 deficiency in an autosomal recessive form of severe combined
RT   immunodeficiency.";
RL   Science 264:1599-1601(1994).
RN   [39]
RP   VARIANT IMD48 HIS-465.
RX   PubMed=11412303; DOI=10.1046/j.1365-2567.2001.01246.x;
RA   Toyabe S., Watanabe A., Harada W., Karasawa T., Uchiyama M.;
RT   "Specific immunoglobulin E responses in ZAP-70-deficient patients are
RT   mediated by Syk-dependent T-cell receptor signalling.";
RL   Immunology 103:164-171(2001).
RN   [40]
RP   VARIANT IMD48 CYS-465.
RX   PubMed=11123350; DOI=10.4049/jimmunol.166.1.656;
RA   Elder M.E., Skoda-Smith S., Kadlecek T.A., Wang F., Wu J., Weiss A.;
RT   "Distinct T cell developmental consequences in humans and mice
RT   expressing identical mutations in the DLAARN motif of ZAP-70.";
RL   J. Immunol. 166:656-661(2001).
RN   [41]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-175; LEU-191; GLU-448 AND LEU-523.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [42]
RP   VARIANTS IMD48 ARG-337; VAL-507 AND ARG-564.
RX   PubMed=18509675; DOI=10.1007/s00431-008-0718-x;
RA   Turul T., Tezcan I., Artac H., de Bruin-Versteeg S., Barendregt B.H.,
RA   Reisli I., Sanal O., van Dongen J.J., van der Burg M.;
RT   "Clinical heterogeneity can hamper the diagnosis of patients with
RT   ZAP70 deficiency.";
RL   Eur. J. Pediatr. 168:87-93(2009).
RN   [43]
RP   VARIANTS ADMIO2 TRP-192 AND PRO-360, CHARACTERIZATION OF VARIANTS
RP   ADMIO2 TRP-192 AND PRO-360, INVOLVEMENT IN ADMIO2, INTERACTION WITH
RP   CD247, AND MUTAGENESIS OF ARG-37; ARG-190; 315-TYR--TYR-319; ASP-327
RP   AND LYS-362.
RX   PubMed=26783323; DOI=10.1084/jem.20150888;
RA   Chan A.Y., Punwani D., Kadlecek T.A., Cowan M.J., Olson J.L.,
RA   Mathes E.F., Sunderam U., Fu S.M., Srinivasan R., Kuriyan J.,
RA   Brenner S.E., Weiss A., Puck J.M.;
RT   "A novel human autoimmune syndrome caused by combined hypomorphic and
RT   activating mutations in ZAP-70.";
RL   J. Exp. Med. 213:155-165(2016).
CC   -!- FUNCTION: Tyrosine kinase that plays an essential role in
CC       regulation of the adaptive immune response. Regulates motility,
CC       adhesion and cytokine expression of mature T-cells, as well as
CC       thymocyte development. Contributes also to the development and
CC       activation of primary B-lymphocytes. When antigen presenting cells
CC       (APC) activate T-cell receptor (TCR), a serie of phosphorylations
CC       lead to the recruitment of ZAP70 to the doubly phosphorylated TCR
CC       component CD247/CD3Z through ITAM motif at the plasma membrane.
CC       This recruitment serves to localization to the stimulated TCR and
CC       to relieve its autoinhibited conformation. Release of ZAP70 active
CC       conformation is further stabilized by phosphorylation mediated by
CC       LCK. Subsequently, ZAP70 phosphorylates at least 2 essential
CC       adapter proteins: LAT and LCP2. In turn, a large number of
CC       signaling molecules are recruited and ultimately lead to
CC       lymphokine production, T-cell proliferation and differentiation.
CC       Furthermore, ZAP70 controls cytoskeleton modifications, adhesion
CC       and mobility of T-lymphocytes, thus ensuring correct delivery of
CC       effectors to the APC. ZAP70 is also required for TCR-CD247/CD3Z
CC       internalization and degradation through interaction with the E3
CC       ubiquitin-protein ligase CBL and adapter proteins SLA and SLA2.
CC       Thus, ZAP70 regulates both T-cell activation switch on and switch
CC       off by modulating TCR expression at the T-cell surface. During
CC       thymocyte development, ZAP70 promotes survival and cell-cycle
CC       progression of developing thymocytes before positive selection
CC       (when cells are still CD4/CD8 double negative). Additionally,
CC       ZAP70-dependent signaling pathway may also contribute to primary
CC       B-cells formation and activation through B-cell receptor (BCR).
CC       {ECO:0000269|PubMed:11353765, ECO:0000269|PubMed:12051764,
CC       ECO:0000269|PubMed:1423621, ECO:0000269|PubMed:20135127,
CC       ECO:0000269|PubMed:26903241, ECO:0000269|PubMed:8124727,
CC       ECO:0000269|PubMed:8702662, ECO:0000269|PubMed:9489702}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:15292186}.
CC   -!- ENZYME REGULATION: Activated by phosphorylation at Tyr-493 in the
CC       activation loop. Inhibited by staurosporine.
CC       {ECO:0000269|PubMed:15292186}.
CC   -!- SUBUNIT: Interacts with CD247/CD3Z; this interaction docks ZAP70
CC       at the stimulated TCR (PubMed:1423621, PubMed:7659156,
CC       PubMed:26783323). Interacts with NFAM1 (PubMed:15143214).
CC       Interacts with adapter protein SLA; this interaction negatively
CC       regulates T-cell receptor signaling (PubMed:10449770). Interacts
CC       with FCRL3 (PubMed:12051764). Interacts with VAV1
CC       (PubMed:9151714). Interacts with CBL; this interaction promotes
CC       ubiquitination, internalization and subsequent degradation of
CC       CD247/CD3Z (PubMed:10449770, PubMed:10078535). Identified in a
CC       complex with CBL and UBE2L3 (PubMed:10966114). Interacts with SHB
CC       (PubMed:12084069). Interacts with adapter protein SLA2; this
CC       interaction negatively regulates T-cell receptor signaling.
CC       Interacts with CBLB. Interacts (via SH2 domains) with RHOH; this
CC       interaction regulates ZAP70 subcellular localization. Interacts
CC       with DEF6 (By similarity). Interacts (ubiquitinated form) with
CC       OTUD7B and UBASH3B (PubMed:26903241).
CC       {ECO:0000250|UniProtKB:P43404, ECO:0000269|PubMed:10078535,
CC       ECO:0000269|PubMed:10449770, ECO:0000269|PubMed:10966114,
CC       ECO:0000269|PubMed:12051764, ECO:0000269|PubMed:12084069,
CC       ECO:0000269|PubMed:1423621, ECO:0000269|PubMed:15143214,
CC       ECO:0000269|PubMed:26783323, ECO:0000269|PubMed:26903241,
CC       ECO:0000269|PubMed:7659156, ECO:0000269|PubMed:9151714}.
CC   -!- INTERACTION:
CC       P20963:CD247; NbExp=22; IntAct=EBI-1211276, EBI-1165705;
CC       P07766:CD3E; NbExp=3; IntAct=EBI-1211276, EBI-1211297;
CC       P00533:EGFR; NbExp=2; IntAct=EBI-1211276, EBI-297353;
CC       P10721:KIT; NbExp=2; IntAct=EBI-1211276, EBI-1379503;
CC       P06239:LCK; NbExp=2; IntAct=EBI-1211276, EBI-1348;
CC       P08581:MET; NbExp=2; IntAct=EBI-1211276, EBI-1039152;
CC       Q9Y2R2:PTPN22; NbExp=4; IntAct=EBI-1211276, EBI-1211241;
CC       Q8BGG7:Ubash3b (xeno); NbExp=10; IntAct=EBI-1211276, EBI-8846415;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9813084}. Cell
CC       membrane {ECO:0000269|PubMed:9813084}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:9813084}. Note=In quiescent T-lymphocytes, it
CC       is cytoplasmic. Upon TCR activation, it is recruited at the plasma
CC       membrane by interacting with CD247/CD3Z. Colocalizes together with
CC       RHOH in the immunological synapse. RHOH is required for its proper
CC       localization to the cell membrane and cytoskeleton fractions in
CC       the thymocytes (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P43403-1; Sequence=Displayed;
CC       Name=2; Synonyms=TZK;
CC         IsoId=P43403-2; Sequence=VSP_031156;
CC       Name=3;
CC         IsoId=P43403-3; Sequence=VSP_031157, VSP_031158;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in T- and natural killer cells. Also
CC       present in early thymocytes and pro/pre B-cells.
CC       {ECO:0000269|PubMed:1423621, ECO:0000269|PubMed:16467082,
CC       ECO:0000269|PubMed:9378960}.
CC   -!- DOMAIN: Composed of 2 N-terminal SH2 domains and a C-terminal
CC       kinase domain. The tandem SH2 domains bind to the doubly
CC       phosphorylated tyrosine-based activation motif (ITAM) of
CC       CD247/CD3Z and the non-canonical phosphorylated tyrosine-based
CC       activation motif (TAM) of RHOH (By similarity). The interdomain B
CC       located between the second SH2 and the kinase domain contains 3
CC       tyrosines (Tyr-292, Tyr-315, Tyr-319) that are phosphorylated
CC       following TCR activation. These sites have been implicated in
CC       binding to other signaling molecules including CBL or VAV1. Thus,
CC       ZAP70 can also function as a scaffold by recruiting additional
CC       factors to the stimulated TCR complex. {ECO:0000250,
CC       ECO:0000269|PubMed:20135127}.
CC   -!- PTM: Phosphorylated on tyrosine residues upon T-cell antigen
CC       receptor (TCR) stimulation. Phosphorylation of Tyr-315 and Tyr-319
CC       are essential for ZAP70 positive function on T-lymphocyte
CC       activation whereas Tyr-292 has a negative regulatory role. Within
CC       the C-terminal kinase domain, Tyr-492 and Tyr-493 are
CC       phosphorylated after TCR induction, Tyr-492 playing a negative
CC       regulatory role and Tyr-493 a positive. Tyr-493 is
CC       dephosphorylated by PTN22. {ECO:0000269|PubMed:10037717,
CC       ECO:0000269|PubMed:1423621, ECO:0000269|PubMed:16339550,
CC       ECO:0000269|PubMed:8943331}.
CC   -!- PTM: Ubiquitinated in response to T cell activation.
CC       Deubiquitinated by OTUD7B. {ECO:0000269|PubMed:26903241}.
CC   -!- DISEASE: Immunodeficiency 48 (IMD48) [MIM:269840]: A form of
CC       severe immunodeficiency characterized by a selective absence of
CC       CD8+ T-cells. {ECO:0000269|PubMed:11123350,
CC       ECO:0000269|PubMed:11412303, ECO:0000269|PubMed:18509675,
CC       ECO:0000269|PubMed:8124727, ECO:0000269|PubMed:8202713}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Autoimmune disease, multisystem, infantile-onset, 2
CC       (ADMIO2) [MIM:617006]: An autosomal recessive, autoimmune disorder
CC       characterized by systemic manifestations including blistering skin
CC       disease, uncontrollable bullous pemphigoid, inflammatory colitis,
CC       autoimmune hypothyroidism, proteinuria and nephrotic syndrome.
CC       {ECO:0000269|PubMed:26783323}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SYK/ZAP-70 subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=ZAP70base; Note=ZAP70 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/ZAP70base/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L05148; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AB083211; BAC43747.1; -; mRNA.
DR   EMBL; AC016699; AAX93187.1; -; Genomic_DNA.
DR   EMBL; BC039039; AAH39039.1; -; mRNA.
DR   EMBL; BC053878; AAH53878.1; -; mRNA.
DR   CCDS; CCDS33254.1; -. [P43403-1]
DR   CCDS; CCDS33255.1; -. [P43403-2]
DR   PIR; A44266; A44266.
DR   PIR; A49955; A49955.
DR   RefSeq; NP_001070.2; NM_001079.3. [P43403-1]
DR   RefSeq; NP_997402.1; NM_207519.1. [P43403-2]
DR   UniGene; Hs.234569; -.
DR   PDB; 1FBV; X-ray; 2.90 A; B=289-297.
DR   PDB; 1M61; X-ray; 2.50 A; A=1-256.
DR   PDB; 1U59; X-ray; 2.30 A; A=327-606.
DR   PDB; 2CBL; X-ray; 2.10 A; B=286-297.
DR   PDB; 2OQ1; X-ray; 1.90 A; A=3-256.
DR   PDB; 2OZO; X-ray; 2.60 A; A=1-606.
DR   PDB; 2Y1N; X-ray; 2.00 A; B/D=286-297.
DR   PDB; 3ZNI; X-ray; 2.21 A; B/F/J/N=286-297.
DR   PDB; 4A4B; X-ray; 2.79 A; B=286-297.
DR   PDB; 4A4C; X-ray; 2.70 A; B=286-297.
DR   PDB; 4K2R; X-ray; 3.00 A; A=1-606.
DR   PDB; 4XZ0; X-ray; 2.00 A; A=1-259.
DR   PDB; 4XZ1; X-ray; 2.80 A; A=1-259.
DR   PDBsum; 1FBV; -.
DR   PDBsum; 1M61; -.
DR   PDBsum; 1U59; -.
DR   PDBsum; 2CBL; -.
DR   PDBsum; 2OQ1; -.
DR   PDBsum; 2OZO; -.
DR   PDBsum; 2Y1N; -.
DR   PDBsum; 3ZNI; -.
DR   PDBsum; 4A4B; -.
DR   PDBsum; 4A4C; -.
DR   PDBsum; 4K2R; -.
DR   PDBsum; 4XZ0; -.
DR   PDBsum; 4XZ1; -.
DR   ProteinModelPortal; P43403; -.
DR   SMR; P43403; -.
DR   BioGrid; 113367; 51.
DR   DIP; DIP-38781N; -.
DR   IntAct; P43403; 21.
DR   MINT; MINT-110540; -.
DR   STRING; 9606.ENSP00000264972; -.
DR   BindingDB; P43403; -.
DR   ChEMBL; CHEMBL2803; -.
DR   DrugBank; DB02010; Staurosporine.
DR   GuidetoPHARMACOLOGY; 2285; -.
DR   iPTMnet; P43403; -.
DR   PhosphoSitePlus; P43403; -.
DR   BioMuta; ZAP70; -.
DR   DMDM; 1177044; -.
DR   MaxQB; P43403; -.
DR   PaxDb; P43403; -.
DR   PeptideAtlas; P43403; -.
DR   PRIDE; P43403; -.
DR   DNASU; 7535; -.
DR   Ensembl; ENST00000264972; ENSP00000264972; ENSG00000115085. [P43403-1]
DR   Ensembl; ENST00000451498; ENSP00000400475; ENSG00000115085. [P43403-2]
DR   GeneID; 7535; -.
DR   KEGG; hsa:7535; -.
DR   UCSC; uc002syd.2; human. [P43403-1]
DR   CTD; 7535; -.
DR   DisGeNET; 7535; -.
DR   GeneCards; ZAP70; -.
DR   GeneReviews; ZAP70; -.
DR   HGNC; HGNC:12858; ZAP70.
DR   HPA; CAB002625; -.
DR   HPA; HPA003134; -.
DR   MalaCards; ZAP70; -.
DR   MIM; 176947; gene.
DR   MIM; 269840; phenotype.
DR   MIM; 617006; phenotype.
DR   neXtProt; NX_P43403; -.
DR   OpenTargets; ENSG00000115085; -.
DR   Orphanet; 911; Combined immunodeficiency due to ZAP70 deficiency.
DR   PharmGKB; PA37447; -.
DR   eggNOG; ENOG410IH0T; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOGENOM; HOG000113264; -.
DR   HOVERGEN; HBG001540; -.
DR   InParanoid; P43403; -.
DR   KO; K07360; -.
DR   OMA; YKARTAG; -.
DR   OrthoDB; EOG091G07KU; -.
DR   PhylomeDB; P43403; -.
DR   TreeFam; TF351629; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-202430; Translocation of ZAP-70 to Immunological synapse.
DR   Reactome; R-HSA-202433; Generation of second messenger molecules.
DR   SignaLink; P43403; -.
DR   SIGNOR; P43403; -.
DR   EvolutionaryTrace; P43403; -.
DR   GeneWiki; ZAP70; -.
DR   GenomeRNAi; 7535; -.
DR   PMAP-CutDB; P43403; -.
DR   PRO; PR:P43403; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000115085; -.
DR   CleanEx; HS_ZAP70; -.
DR   Genevisible; P43403; HS.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; TAS:HGNC.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0001772; C:immunological synapse; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0042101; C:T cell receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; NAS:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0002250; P:adaptive immune response; TAS:UniProtKB.
DR   GO; GO:0042113; P:B cell activation; TAS:UniProtKB.
DR   GO; GO:0043366; P:beta selection; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; NAS:UniProtKB.
DR   GO; GO:0045060; P:negative thymic T cell selection; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:0046638; P:positive regulation of alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0046641; P:positive regulation of alpha-beta T cell proliferation; IEA:Ensembl.
DR   GO; GO:0050850; P:positive regulation of calcium-mediated signaling; IEA:Ensembl.
DR   GO; GO:0045582; P:positive regulation of T cell differentiation; IDA:MGI.
DR   GO; GO:0045059; P:positive thymic T cell selection; IDA:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0042110; P:T cell activation; TAS:UniProtKB.
DR   GO; GO:0070489; P:T cell aggregation; TAS:UniProtKB.
DR   GO; GO:0030217; P:T cell differentiation; NAS:UniProtKB.
DR   GO; GO:0072678; P:T cell migration; TAS:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 1.10.930.10; -; 1.
DR   Gene3D; 3.30.505.10; -; 2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR023420; Kinase_SYK/ZAP-70_inter-SH2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR012234; Tyr_kinase_non-rcpt_SYK/ZAP70.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 2.
DR   PIRSF; PIRSF000604; TyrPK_SYK; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF55550; SSF55550; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Adaptive immunity; Alternative splicing;
KW   ATP-binding; Cell membrane; Complete proteome; Cytoplasm;
KW   Disease mutation; Immunity; Isopeptide bond; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; SCID; SH2 domain; Transferase; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   CHAIN         1    619       Tyrosine-protein kinase ZAP-70.
FT                                /FTId=PRO_0000088168.
FT   DOMAIN       10    102       SH2 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      163    254       SH2 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      338    600       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     345    352       ATP.
FT   REGION      103    162       Interdomain A.
FT   REGION      255    337       Interdomain B.
FT   ACT_SITE    461    461       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028,
FT                                ECO:0000269|PubMed:15292186,
FT                                ECO:0000269|PubMed:17512407}.
FT   BINDING     369    369       ATP.
FT   MOD_RES     248    248       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES     289    289       Phosphoserine.
FT                                {ECO:0000244|PubMed:15144186}.
FT   MOD_RES     292    292       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000269|PubMed:8943331}.
FT   MOD_RES     315    315       Phosphotyrosine; by LCK.
FT                                {ECO:0000269|PubMed:10037717}.
FT   MOD_RES     319    319       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:10037717}.
FT   MOD_RES     492    492       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:7781602}.
FT   MOD_RES     493    493       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:7781602}.
FT   MOD_RES     603    603       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   CROSSLNK    544    544       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:26903241}.
FT   VAR_SEQ       1    307       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14985102}.
FT                                /FTId=VSP_031156.
FT   VAR_SEQ       1    126       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_031157.
FT   VAR_SEQ     127    134       VRQTWKLE -> MRLGPRWK (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_031158.
FT   VARIANT     175    175       R -> L (in dbSNP:rs55964305).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041846.
FT   VARIANT     191    191       P -> L (in dbSNP:rs56403250).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041847.
FT   VARIANT     192    192       R -> W (in ADMIO2; decreases interaction
FT                                with phosphorylated CD247; decreases
FT                                ZAP70 phosphorylation; no effect on
FT                                subcellular localization of CD69 at the
FT                                cell surface; dbSNP:rs199840952).
FT                                {ECO:0000269|PubMed:26783323}.
FT                                /FTId=VAR_077137.
FT   VARIANT     337    337       L -> R (in IMD48).
FT                                {ECO:0000269|PubMed:18509675}.
FT                                /FTId=VAR_065623.
FT   VARIANT     360    360       R -> P (in ADMIO2; no effect on
FT                                interaction with phosphorylated CD247;
FT                                increases TCR-induced Y-319 and Y-493
FT                                phosphorylation of ZAP70 and
FT                                phosphorylation of LAT and LCP2;
FT                                increases subcellular localization of
FT                                CD69 at the cell surface; weakly
FT                                decreases autoinhibition conformation;
FT                                dbSNP:rs869025224).
FT                                {ECO:0000269|PubMed:26783323}.
FT                                /FTId=VAR_077138.
FT   VARIANT     448    448       G -> E (in a head and neck squamous cell
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041848.
FT   VARIANT     465    465       R -> C (in IMD48; dbSNP:rs113994174).
FT                                {ECO:0000269|PubMed:11123350}.
FT                                /FTId=VAR_065624.
FT   VARIANT     465    465       R -> H (in IMD48; dbSNP:rs137853201).
FT                                {ECO:0000269|PubMed:11412303}.
FT                                /FTId=VAR_015538.
FT   VARIANT     507    507       A -> V (in IMD48).
FT                                {ECO:0000269|PubMed:18509675}.
FT                                /FTId=VAR_065625.
FT   VARIANT     518    518       S -> R (in IMD48; dbSNP:rs104893674).
FT                                {ECO:0000269|PubMed:8202713}.
FT                                /FTId=VAR_006351.
FT   VARIANT     523    523       W -> L (in dbSNP:rs56189815).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041849.
FT   VARIANT     541    541       K -> KLEQ (in IMD48).
FT                                {ECO:0000269|PubMed:8124727}.
FT                                /FTId=VAR_038688.
FT   VARIANT     564    564       C -> R (in IMD48).
FT                                {ECO:0000269|PubMed:18509675}.
FT                                /FTId=VAR_065626.
FT   MUTAGEN      37     37       R->K: Decreases interaction with
FT                                phosphorylated CD247; when associated
FT                                with K-190.
FT                                {ECO:0000269|PubMed:26783323}.
FT   MUTAGEN     131    131       W->A: Increased constitutive kinase
FT                                activity. {ECO:0000269|PubMed:17512407}.
FT   MUTAGEN     133    133       L->A: Increased constitutive kinase
FT                                activity. {ECO:0000269|PubMed:17512407}.
FT   MUTAGEN     141    141       A->E: Increased constitutive kinase
FT                                activity. {ECO:0000269|PubMed:17512407}.
FT   MUTAGEN     144    144       S->A: Increased kinase activity after
FT                                activation by LCK.
FT                                {ECO:0000269|PubMed:17512407}.
FT   MUTAGEN     145    145       Q->A: Increased kinase activity after
FT                                activation by LCK.
FT                                {ECO:0000269|PubMed:17512407}.
FT   MUTAGEN     147    147       P->A: Increased kinase activity after
FT                                activation by LCK.
FT                                {ECO:0000269|PubMed:17512407}.
FT   MUTAGEN     190    190       R->K: Decreases interaction with
FT                                phosphorylated CD247; when associated
FT                                with K-37. {ECO:0000269|PubMed:26783323}.
FT   MUTAGEN     292    292       Y->F: Induces constitutive TCR
FT                                stimulation-independent NFAT induction.
FT                                {ECO:0000269|PubMed:8943331}.
FT   MUTAGEN     304    304       K->R: No effect on ubiquitination.
FT                                {ECO:0000269|PubMed:26903241}.
FT   MUTAGEN     314    314       V->A: Increased constitutive kinase
FT                                activity.
FT   MUTAGEN     315    319       YESPY->AESPA: Increases strongly
FT                                constitutive kinase activity on LAT
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:26783323}.
FT   MUTAGEN     315    315       Y->A: Increased constitutive kinase
FT                                activity; when associated with F-319.
FT                                {ECO:0000269|PubMed:10037717,
FT                                ECO:0000269|PubMed:11828374,
FT                                ECO:0000269|PubMed:17512407,
FT                                ECO:0000269|PubMed:9151714}.
FT   MUTAGEN     315    315       Y->F: Increased constitutive kinase
FT                                activity; when associated with F-319.
FT                                About 75% loss of CD247/CD3Z-binding in
FT                                stimulated TCR and complete loss of VAV1
FT                                interaction.
FT                                {ECO:0000269|PubMed:10037717,
FT                                ECO:0000269|PubMed:11828374,
FT                                ECO:0000269|PubMed:17512407,
FT                                ECO:0000269|PubMed:9151714}.
FT   MUTAGEN     319    319       Y->A: Increased constitutive kinase
FT                                activity; when associated with F-315.
FT                                {ECO:0000269|PubMed:10037717,
FT                                ECO:0000269|PubMed:17512407}.
FT   MUTAGEN     319    319       Y->F: Increased constitutive kinase
FT                                activity; when associated with F-315.
FT                                About 80% loss of TCR-induced NFAT
FT                                activation. {ECO:0000269|PubMed:10037717,
FT                                ECO:0000269|PubMed:17512407}.
FT   MUTAGEN     327    327       D->P: Increases constitutive kinase
FT                                activity on LAT phosphorylation, strongly
FT                                increases subcellular localization of
FT                                CD69 at the cell surface and decreases
FT                                autoinhibition conformation.
FT                                {ECO:0000269|PubMed:26783323}.
FT   MUTAGEN     362    362       K->E: Increases constitutive kinase
FT                                activity on LAT phosphorylation, strongly
FT                                increases subcellular localization of
FT                                CD69 at the cell surface and decreases
FT                                autoinhibition conformation.
FT                                {ECO:0000269|PubMed:26783323}.
FT   MUTAGEN     461    461       D->N: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:17512407}.
FT   MUTAGEN     479    479       D->N: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:15292186}.
FT   MUTAGEN     492    492       Y->F: Increases kinase activity.
FT                                {ECO:0000269|PubMed:7781602}.
FT   MUTAGEN     493    493       Y->F: Impairs kinase activity.
FT                                {ECO:0000269|PubMed:7781602}.
FT   MUTAGEN     538    538       K->R: No effect on ubiquitination.
FT                                {ECO:0000269|PubMed:26903241}.
FT   MUTAGEN     544    544       K->R: Strongly decreased ubiquitination.
FT                                {ECO:0000269|PubMed:26903241}.
FT   MUTAGEN     597    597       Y->A: Increased kinase activity after
FT                                activation by LCK.
FT                                {ECO:0000269|PubMed:17512407}.
FT   MUTAGEN     598    598       Y->A: Increased kinase activity after
FT                                activation by LCK.
FT                                {ECO:0000269|PubMed:17512407}.
FT   TURN          4      7       {ECO:0000244|PDB:2OQ1}.
FT   STRAND       11     14       {ECO:0000244|PDB:1M61}.
FT   HELIX        17     26       {ECO:0000244|PDB:2OQ1}.
FT   STRAND       34     38       {ECO:0000244|PDB:2OQ1}.
FT   STRAND       40     42       {ECO:0000244|PDB:2OQ1}.
FT   STRAND       46     52       {ECO:0000244|PDB:2OQ1}.
FT   STRAND       55     63       {ECO:0000244|PDB:2OQ1}.
FT   STRAND       69     71       {ECO:0000244|PDB:2OQ1}.
FT   STRAND       77     79       {ECO:0000244|PDB:2OQ1}.
FT   HELIX        80     89       {ECO:0000244|PDB:2OQ1}.
FT   STRAND       94     96       {ECO:0000244|PDB:2OQ1}.
FT   HELIX       114    131       {ECO:0000244|PDB:2OQ1}.
FT   HELIX       135    156       {ECO:0000244|PDB:2OQ1}.
FT   HELIX       157    160       {ECO:0000244|PDB:2OQ1}.
FT   HELIX       170    178       {ECO:0000244|PDB:2OQ1}.
FT   TURN        179    181       {ECO:0000244|PDB:1M61}.
FT   STRAND      186    191       {ECO:0000244|PDB:2OQ1}.
FT   STRAND      197    204       {ECO:0000244|PDB:2OQ1}.
FT   STRAND      207    215       {ECO:0000244|PDB:2OQ1}.
FT   TURN        217    219       {ECO:0000244|PDB:4XZ1}.
FT   STRAND      221    223       {ECO:0000244|PDB:2OQ1}.
FT   STRAND      229    231       {ECO:0000244|PDB:2OQ1}.
FT   HELIX       232    241       {ECO:0000244|PDB:2OQ1}.
FT   STRAND      246    248       {ECO:0000244|PDB:2OQ1}.
FT   HELIX       309    311       {ECO:0000244|PDB:4K2R}.
FT   STRAND      316    320       {ECO:0000244|PDB:2OZO}.
FT   HELIX       322    326       {ECO:0000244|PDB:4K2R}.
FT   HELIX       334    336       {ECO:0000244|PDB:1U59}.
FT   STRAND      337    345       {ECO:0000244|PDB:1U59}.
FT   STRAND      350    357       {ECO:0000244|PDB:1U59}.
FT   STRAND      364    371       {ECO:0000244|PDB:1U59}.
FT   HELIX       377    392       {ECO:0000244|PDB:1U59}.
FT   STRAND      401    415       {ECO:0000244|PDB:1U59}.
FT   HELIX       422    426       {ECO:0000244|PDB:1U59}.
FT   TURN        430    432       {ECO:0000244|PDB:1U59}.
FT   HELIX       435    454       {ECO:0000244|PDB:1U59}.
FT   HELIX       464    466       {ECO:0000244|PDB:1U59}.
FT   STRAND      467    471       {ECO:0000244|PDB:1U59}.
FT   STRAND      474    477       {ECO:0000244|PDB:1U59}.
FT   TURN        482    485       {ECO:0000244|PDB:2OZO}.
FT   HELIX       503    505       {ECO:0000244|PDB:1U59}.
FT   HELIX       508    513       {ECO:0000244|PDB:1U59}.
FT   HELIX       518    533       {ECO:0000244|PDB:1U59}.
FT   TURN        534    536       {ECO:0000244|PDB:4K2R}.
FT   TURN        539    542       {ECO:0000244|PDB:1U59}.
FT   HELIX       546    553       {ECO:0000244|PDB:1U59}.
FT   HELIX       566    574       {ECO:0000244|PDB:1U59}.
FT   HELIX       580    582       {ECO:0000244|PDB:1U59}.
FT   HELIX       586    601       {ECO:0000244|PDB:1U59}.
SQ   SEQUENCE   619 AA;  69872 MW;  D1E1A8EC66FA116F CRC64;
     MPDPAAHLPF FYGSISRAEA EEHLKLAGMA DGLFLLRQCL RSLGGYVLSL VHDVRFHHFP
     IERQLNGTYA IAGGKAHCGP AELCEFYSRD PDGLPCNLRK PCNRPSGLEP QPGVFDCLRD
     AMVRDYVRQT WKLEGEALEQ AIISQAPQVE KLIATTAHER MPWYHSSLTR EEAERKLYSG
     AQTDGKFLLR PRKEQGTYAL SLIYGKTVYH YLISQDKAGK YCIPEGTKFD TLWQLVEYLK
     LKADGLIYCL KEACPNSSAS NASGAAAPTL PAHPSTLTHP QRRIDTLNSD GYTPEPARIT
     SPDKPRPMPM DTSVYESPYS DPEELKDKKL FLKRDNLLIA DIELGCGNFG SVRQGVYRMR
     KKQIDVAIKV LKQGTEKADT EEMMREAQIM HQLDNPYIVR LIGVCQAEAL MLVMEMAGGG
     PLHKFLVGKR EEIPVSNVAE LLHQVSMGMK YLEEKNFVHR DLAARNVLLV NRHYAKISDF
     GLSKALGADD SYYTARSAGK WPLKWYAPEC INFRKFSSRS DVWSYGVTMW EALSYGQKPY
     KKMKGPEVMA FIEQGKRMEC PPECPPELYA LMSDCWIYKW EDRPDFLTVE QRMRACYYSL
     ASKVEGPPGS TQKAEAACA
//
